ECCO 2025

Eating is part of life – and of special therapeutic…

Surgical approaches in IBD – all questions solved?

No treatment choices anymore? Efficacy and safety of…

The importance of endoscopic surveillance – current…

New UC-kids on the block: a IL7 receptor antagonist &…

Anti-TL1a – a new treatment option in IBD and unsolved…

Comparative efficacy between biologics in UC – the need…

Comparative efficacy and safety – do we need to…

Update on fistulizing disease

Old vs. new – ustekinumab vs. modern IL23

Urgency – what is hen and what is egg?

What is the best treatment goal for moderate to severe…

Autologous HSCT – still an option for refractory CD?

Early CD treatment with vedolizumab

Subcutaneous induction with guselkumab in CD is…

The need for early treatment in Crohn’s disease – a…

Dose escalation of vedolizumab in CD is not effective

Kono-S anastomosis is not superior to side-to-side…

La anastomosis Kono-S no es superior a la anastomosis…

Rola wczesnej terapii choroby Leśniowskiego-Crohna –…

HSCT autologue – toujours une option pour la maladie de…

Obefazimod maintenance treatment: a new approach

Appendectomy – a good option for UC

How to treat UC patients after failure of a s.c.…

Long-term efficacy and safety of a lower obefazimod…

First combination of upadacitinib and vedolizumab in…

Personalized dosing in acute UC

Obefazimod in der Erhaltung: Neuer Ansatz

Long-term efficacy and safety of a lower obefazimod…

Subkutane Therapie mit Guselkumab bei Morbus Crohn und…

Appendektomie – eine gute Option bei Colitis Ulcerosa

Erste Kombination von Upadacitinib und Vedolizumab bei…

s.c.? i.v.? Just swallow it! News from the oral…

New treatments – fast forward to the future

SOR102 – a novel oral bispecific antibody in patients…

A new class of drugs: anti-TL1A antibodies

New mode of action for treating UC

Nouveau mode d'action pour le traitement de la RCH

SOR102 – un nuovo anticorpo bispecifico orale in…

Lusvertikimab – un antagonista del recettore IL7 di…

טיפולים חדשים- fast forward לעתיד

s.c.? i.v.? Einfach schlucken! Neues vom oralen…

Minimal Residual Disease: a new treatment goal in IBD?

Mirikizumab demonstrates rapid improvements in bowel…

Comprehensive approach necessary to treat our patients…

Defining radiological healing in perianal fistulising…

What is the best treatment goal for moderate to severe…

גישה כוללנית הכרחית לטיפול בחולים בדרך המיטבית

Definiendo la curación radiológica en enfermedad de…

Mirikizumab demonstrates rapid improvements in bowel…

Minimal Residual Disease: ein neuer Endpunkt bei CED?

Tasty&Healthy – the next step towards anti-inflammatory…

Tasty&Healthy diet is better tolerated than exclusive…

A low emulsifier diet is a treatment for moderate to…

Spożycie błonnika a ryzyko zachorowania na chorobę…

Comparative efficacy of infliximab and vedolizumab…

ASTRO study established the efficacy of guselkumab…

PODIUM: effectiveness & safety of 2nd line vedolizumab…

Effectiveness & safety of advanced combination therapy…

PODIUM: efficacia e sicurezza di Vedolizumab o…

Eficacia comparativa de infliximab vs. vedolizumab tras…

El estudio ASTRO demuestra la eficacia de Guselkumab en…

Dose escalation of primary non-responders is not…

Infliximab induction fails to reach target drug level…

Second line treatment for perianal Crohn's disease

Optimizing biologics in CD – is it relevant for all?

Efficacia e sicurezza di una terapia combinata avanzata…

אופטימיזציה של תכשירים ביולוגים במחלת קרוהן-האם מתאים…

Mancato aumento dei livelli terapeutici di IFX nella…

Risk of IMID associated with anti-TNF and ustekinumab…

Rischio di IMID associato al trattamento con anti-TNF e…

How to detect preneoplastic lesions by coloscopy

αvβ6 – ein neuer Biomarker zur Prädiktion, Staging und…

Identification of CD and UC specific clonotypes

סיווג HLA-התקדמות בטיפול מותאם אישית?